Leadership Team

David P. Hochman

Chairman of the Board of Directors, Chief Executive Officer and Founder

Mr. Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. Since 2006, he has been Managing Partner of Orchestra Medical Ventures, LLC (“Orchestra Medical Ventures”), an investment firm that employs a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value.

Darren R. Sherman

President, Chief Operating Officer, Director and Founder

Mr. Sherman has served as President, Chief Operating Officer and a member of the Board of Orchestra BioMed since May 2018. Since 2009, Mr. Sherman has been Managing Partner of Orchestra Medical Ventures, an investment firm that employs a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value.

C. Evan Ballantyne

Chief Financial Officer and Secretary

Mr. Ballantyne became Chief Financial Officer of Orchestra BioMed in October 2018. He is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years.

Yuval Mika, Ph. D.

General Manager and Chief Technology Officer, Bioelectronic Therapies

Dr. Mika has served as General Manager and Chief Technology Officer of Orchestra BioMed’s Bioelectronic Therapies development group since May 2018. Since 2011, Dr. Mika served as the CEO of BackBeat Medical, Inc.  He was one of the founders of BackBeat and the leader in the development of BackBeat Cardiac Neuromodulation Therapy from concept and design of the device through preclinical and clinical work demonstrating the effect of the therapy in lowering blood pressure.

Inessa R. Wheeler

Vice President, Strategy & Marketing

Prior to joining Orchestra BioMed in September 2018, Ms. Wheeler served since 2010 as President of D&E Strategy, LLC, a business strategy and marketing consulting firm which provides services to established as well as start-up medical device and pharmaceutical companies.

Dennis Donohoe, M.D.

Chief Medical Officer

Dennis Donohoe, M.D. has served as Chief Medical Officer of Orchestra BioMed since October 2018. Previously, he served as Chief Medical Officer for Orchestra BioMed’s Focal Therapies development group and its predecessor, Caliber Therapeutics.

Ziv Belsky

Vice President, Research & Development, Bioelectronic Therapies

Prior to joining Orchestra BioMed in August 2018, Mr. Belsky was Chief Technology Officer for NewPace Ltd., a cardiac rhythm management company based in Israel that is developing an implantable subcutaneous string defibrillator device for patients with atrial fibrillation.

Daniel Burkhoff, M.D., PhD.

Senior Director, Scientific & Medical Affairs, Bioelectronic Therapies

Dr. Burkhoff has served as Senior Director, Scientific & Medical Affairs, Bioelectronic Therapies for Orchestra BioMed since May 2018. Previously, he served Chairman of the Scientific Advisory Board as well as Scientific Director of BackBeat Medical under a consulting agreement since 2010.

Eileen Bailey

Vice President of Quality and Regulatory Affairs

Ms. Eileen Bailey has served as the Vice President of Quality and Regulatory Affairs for Orchestra BioMed since May 2018. Previously, she served in various quality, regulatory and clinical roles for Orchestra BioMed’s Focal Therapies development group and its predecessor, Caliber Therapeutics, beginning in March 2012.

Steven Evans, M.D.

Medical Director, Bioelectronic Therapies

Dr. Evans has served as Medical Director, Bioelectronic Therapies for Orchestra BioMed since May 2018. Previously, he served Chief Medical Officer of BackBeat Medical under a consulting agreement since 2011.

Norbert Rosenthal

Director, Clinical & Technical Operations, Bioelectronic Therapies

Mr. Norbert Rosenthal has served as the Clinical Director and Technical Manager of Orchestra BioMed’s Bioelectronic Therapies development group since May 2018. He served in the same capacity for BackBeat Medical, Inc. since 2013, supporting BackBeat's clinical trials in Europe.

Jürgen Bernhard, Ph.D.

Director, Clinical Operations, Bioelectronic Therapies

Dr. Jürgen Bernhard has served as Director, Clinical Operations of Orchestra BioMed’s Bioelectronic Therapies development group since May 2018. He served in the same capacity for BackBeat Medical, Inc. since 2014, supporting BackBeat's clinical trials in Europe.

William Baumbach, Ph.D.

Vice President, Scientific Affairs, Focal Therapies

Dr. Baumbach, Ph.D. has served as Vice President, Scientific Affairs for Orchestra BioMed’s Focal Therapies development group since May 2018. He over 30 years of experience in pharmaceutical, biotechnology, and medical device R&D.

Ron Dadino

Vice President, Pharmaceutical Development & Operations, Focal Therapies

Prior to joining Orchestra BioMed in August 2018, Mr. Dadino was Vice President, Pharmaceutical Development and Manufacturing for Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology.

Have any questions?
Contact us at 917.254.4900 or info@orchestrabiomed.com